Clearmind Medicine Announces $600,000 Convertible Promissory Note Financing

On May 18, 2026, Clearmind Medicine Inc. announced that it entered into an agreement with CLA Investors to issue and sell convertible promissory notes in the aggregate principal amount of $600,000. This transaction is conducted under an existing amendment to securities purchase agreements (SPAs) originally dated September 17, 2025, which allows for the issuance of up to $10,000,000 in aggregate principal amount of promissory notes. The current $600,000 notes are being sold at an aggregate purchase price of $540,000, representing 90% of the principal amount. The transaction is expected to close on or about May 19, 2026. The proceeds will provide the company with additional working capital. This filing is incorporated by reference into several of the company's existing registration statements on Form F-3 and Form S-8. Clearmind Medicine is a biotech company focusing on the development of psychedelic-derived therapeutics.